#antibodies

Evidence is growing that contracting SARS-CoV-2 is generally as effective as vaccination at preventing COVID-19.

People who received the Moderna COVID-19 vaccine had strong immune memory of SARS-CoV-2 six months after vaccination.

About half of people hospitalized with COVID-19 had antibodies that could mistakenly attack the body’s own proteins and tissues.

With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.

Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.

Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.

The CDC recommends that everyone ages 13 to 64 get a routine HIV test at least once.

The new prevention approach shows promise, but it isn’t heading to the clinic anytime soon.

We got COVID-19 vaccines in record time. Why are HIV vaccines taking so long?

Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.

More than 95% of people who recovered from COVID-19 had durable immune system memory up to eight months after infection.

Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.

The new prevention approach shows promise, but it isn’t heading to the clinic anytime soon.

Long-lived memory immune cells continue to provide protection even after antibody levels drop.

People who have had evidence of a prior infection appear to have some degree of protection against being reinfected with the virus.

Immune cells called T cells helped prevent reinfection and may be especially important if antibody levels are low or decline over time.